Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 55-74
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.55
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.55
Prevalence of H. pylori | Diagnostic tool of H. pylori | Study design | P value | |
Helicobacter and Cancer Collaborative Group[68] | Non-cardia GC: OR: 5.9; 95%CI: 3.4-10.3 | Serology and/or histology | Meta-analysis | P = 0.002 |
Huang et al[66] | For cagA-positive OR: 1.64; 95%CI: 1.21-2.241 | Serology and/or histology | Meta-analysis | NA |
Gastric cancer incidence decreased after H. pylori eradication | ||||
Lee et al[70] | Incidence rate ratio = 0.53; 95%CI: 0.44-0.64 | Serology and/or histology; rapid urease test | Meta-analysis | NA |
Chiang et al[71] | Reducing GC incidence of 0.53; 95%CI :0.3-0.69 | Rapid urease test | Prospective study | P < 0.001 |
- Citation: Kuo YC, Yu LY, Wang HY, Chen MJ, Wu MS, Liu CJ, Lin YC, Shih SC, Hu KC. Effects of Helicobacter pylori infection in gastrointestinal tract malignant diseases: From the oral cavity to rectum. World J Gastrointest Oncol 2022; 14(1): 55-74
- URL: https://www.wjgnet.com/1948-5204/full/v14/i1/55.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i1.55